Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

Introduction: BRAF mutations are rare in patients with NSCLC, and treatment options are limited. Dabrafenib plus trametinib (dab-tram) was approved for BRAFV600-mutated advanced NSCLC (aNSCLC), based on results from a phase 2 study (NCT01336634). This retrospective analysis compared the effectivenes...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bruce E. Johnson, MD, Christina S. Baik, MD, Julien Mazieres, MD, Harry J.M. Groen, MD, Barbara Melosky, MD, Jürgen Wolf, MD, Fatemeh Asad Zadeh Vosta Kolaei, PhD, Wen-Hsing Wu, MS, Stefanie Knoll, PhD, Meryem Ktiouet Dawson, MD, Adam Johns, PhD, David Planchard, MD
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2022-05-01
Col·lecció:	JTO Clinical and Research Reports
Matèries:	BRAF inhibitor MEK inhibitor BRAF-mutated aNSCLC Indirect comparison Platinum-based chemotherapy Immune-checkpoint inhibitors
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666364322000480
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!